Efficacy and Safety for Different Regimen of VTE Pharmacoprophylaxis Among Severely Burn Patients
NCT05237726 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2022-12-20
Summary
This study aims to assess the feasibility and safety of VTE prophylaxis for 3 modality regimens (Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours) in adult patients (≥18 y/o) with severely burn injuries (BSA≥20%) by measuring the bleeding incidence and VTE events.
Conditions
- Burns
Interventions
- DRUG
-
Enoxaparin 40 mg q24 hours
Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
- DRUG
-
Enoxaparin 30 mg q12 hours
Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
- DRUG
-
Unfractionated heparin 5000 U q8 hours
Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
Sponsors & Collaborators
-
King Abdullah International Medical Research Center
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-04-05
- Primary Completion
- 2022-02-28
- Completion
- 2022-02-28
Countries
- Saudi Arabia
Study Locations
More Related Trials
-
A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness
NCT05819112 ·Status: TERMINATED
-
EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
NCT00077753 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Chemical Venous Thromboembolism Prophylaxis in Trauma
NCT06025162 ·Status: UNKNOWN
-
Pharmacokinetics of Enoxaparin in Intensive Care Patients
NCT02095509 ·Status: COMPLETED ·Phase: PHASE4
-
Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
NCT01729559 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients
NCT02412982 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin
NCT00622648 ·Status: COMPLETED ·Phase: PHASE4
-
Thrombelastography Based Dosing of Enoxaparin
NCT00990236 ·Status: COMPLETED ·Phase: NA
-
Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test.
NCT04710732 ·Status: TERMINATED ·Phase: PHASE4
-
Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT
NCT04504318 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety Study of Enoxaparin Prophylaxis in Critically Ill Adults With Severe Renal Insufficiency
NCT02690090 ·Status: UNKNOWN
-
Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery
NCT00723216 ·Status: COMPLETED ·Phase: PHASE3
-
Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose
NCT02704052 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility
NCT00714597 ·Status: TERMINATED ·Phase: PHASE3
-
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
NCT00331838 ·Status: COMPLETED ·Phase: PHASE2
-
Thromboprophylaxis in Critically Ill Patients
NCT00437697 ·Status: TERMINATED ·Phase: PHASE4
-
Enoxaparin Versus Placebo for Venous Thromboembolism Prevention in Low Risk Cancer Patients After Surgical Procedures: a Randomized, Double Blind, Placebo Controlled Clinical Trial Pilot Study
NCT03988231 ·Status: WITHDRAWN ·Phase: PHASE4
-
Enoxaparin Metabolism in Reconstructive Surgery Patients
NCT02411292 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
NCT03891524 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Sodium Heparin in Prophylaxis of Venous Thromboembolism in Surgical Patients
NCT00912483 ·Status: WITHDRAWN ·Phase: PHASE3
-
Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients
NCT02707263 ·Status: WITHDRAWN ·Phase: NA
-
Comparative Study of the Hemorrhagic Risk in Patients Over 75 Years of Age Taking Enoxaparin
NCT05150314 ·Status: UNKNOWN
-
Timing of VTE Prophylaxis in TBI
NCT03081169 ·Status: WITHDRAWN ·Phase: PHASE4
-
Adjusted Value of Thromboprophylaxis in Hospitalized Obese Patients: A Comparative Study of Two Regimens of Enoxaparin
NCT01707732 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients
NCT00351663 ·Status: COMPLETED ·Phase: PHASE4